Literature DB >> 30171879

Late Effects of Radiation Prime the Brain Microenvironment for Accelerated Tumor Growth.

Chong Duan1, Ruimeng Yang2, Liya Yuan3, John A Engelbach4, Christina I Tsien5, Keith M Rich6, Sonika M Dahiya7, Tanner M Johanns8, Joseph J H Ackerman9, Joel R Garbow10.   

Abstract

PURPOSE: Glioblastoma (GBM) remains incurable, despite state-of-the-art treatment involving surgical resection, chemotherapy, and radiation. GBM invariably recurs as a highly invasive and aggressive phenotype, with the majority of recurrences within the radiation therapy treatment field. Although a large body of literature reporting on primary GBM exists, comprehensive studies of how prior irradiation alters recurrent tumor growth are lacking. An animal model that replicates the delayed effects of radiation therapy on the brain microenvironment, and its impact on the development of recurrent GBM, would be a significant advance. METHODS AND MATERIALS: Cohorts of mice received a single fraction of 0, 20, 30, or 40 Gy Gamma Knife irradiation. Naïve, nonirradiated mouse GBM tumor cells were implanted into the ipsilateral hemisphere 6 weeks postirradiation. Tumor growth was measured by magnetic resonance imaging, and animal survival was assessed by monitoring weight loss. Magnetic resonance imaging results were supported by hemotoxylin and eosin histology.
RESULTS: Tumorous lesions generated from orthotopic implantation of nonirradiated mouse GBM tumor cells into irradiated mouse brain grew far more aggressively and invasively than implantation of these same cells into nonirradiated brain. Lesions in irradiated brain tissue were significantly larger, more necrotic, and more vascular than those in control animals with increased invasiveness of tumor cells in the periphery, consistent with the histologic features commonly observed in recurrent high-grade tumors in patients.
CONCLUSIONS: Irradiation of normal brain primes the targeted cellular microenvironment for aggressive tumor growth when naïve (not previously irradiated) cancer cells are subsequently introduced. The resultant growth pattern is similar to the highly aggressive pattern of tumor regrowth observed clinically after therapeutic radiation therapy. The mouse model offers an avenue for determining the cellular and molecular basis for the aggressiveness of recurrent GBM.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30171879      PMCID: PMC6849509          DOI: 10.1016/j.ijrobp.2018.08.033

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

Review 1.  Status quo--standard-of-care medical and radiation therapy for glioblastoma.

Authors:  Kevin P Becker; James Yu
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Radiation resistance and stem-like cells in brain tumors.

Authors:  Dolores Hambardzumyan; Massimo Squatrito; Massimo Squartro; Eric C Holland
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

Review 3.  Cancer stem cells.

Authors:  Craig T Jordan; Monica L Guzman; Mark Noble
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

4.  Can anti-vascular endothelial growth factor antibody reverse radiation necrosis? A preclinical investigation.

Authors:  Chong Duan; Carlos J Perez-Torres; Liya Yuan; John A Engelbach; Scott C Beeman; Christina I Tsien; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

5.  3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation.

Authors:  U Oppitz; D Maessen; H Zunterer; S Richter; M Flentje
Journal:  Radiother Oncol       Date:  1999-10       Impact factor: 6.280

6.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

7.  In vivo imaging in a murine model of glioblastoma.

Authors:  Sarah C Jost; John E Wanebo; Sheng-Kwei Song; Michael R Chicoine; Keith M Rich; Thomas A Woolsey; Jason S Lewis; Robert H Mach; Jinbin Xu; Joel R Garbow
Journal:  Neurosurgery       Date:  2007-02       Impact factor: 4.654

8.  Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma.

Authors:  C Wild-Bode; M Weller; A Rimner; J Dichgans; W Wick
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

9.  Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost.

Authors:  P K Sneed; P H Gutin; D A Larson; M K Malec; T L Phillips; M D Prados; C O Scharfen; K A Weaver; W M Wara
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-01       Impact factor: 7.038

10.  Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis.

Authors:  Shu-Chi Wang; Ching-Fang Yu; Ji-Hong Hong; Chien-Sheng Tsai; Chi-Shiun Chiang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more
  11 in total

1.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

2.  Distinguishing Tumor Admixed in a Radiation Necrosis (RN) Background: 1H and 2H MR With a Novel Mouse Brain-Tumor/RN Model.

Authors:  Xia Ge; Kyu-Ho Song; John A Engelbach; Liya Yuan; Feng Gao; Sonika Dahiya; Keith M Rich; Joseph J H Ackerman; Joel R Garbow
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

3.  Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?

Authors:  Christina Tsien
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 4.  Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications.

Authors:  Kshama Gupta; Terry C Burns
Journal:  Front Oncol       Date:  2018-11-08       Impact factor: 6.244

5.  Test-Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.

Authors:  Xia Ge; James D Quirk; John A Engelbach; G Larry Bretthorst; Shunqiang Li; Kooresh I Shoghi; Joel R Garbow; Joseph J H Ackerman
Journal:  Tomography       Date:  2019-09

6.  Cell aging related genes can be used to characterize clinical prognoses and further stratify diffuse gliomas.

Authors:  Yang Yang; Xin Chen; Jianjun Sun; Suhua Chen; Chenlong Yang; Qianquan Ma; Jun Yang
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

7.  Limited field adaptive radiotherapy for glioblastoma: changes in target volume and organ at risk doses.

Authors:  Öznur Şenkesen; Evrim Tezcanlı; Mehmet Ufuk Abacıoğlu; Zeynep Özen; Derya Çöne; Halil Küçücük; Evren Ozan Göksel; Alptekin Arifoğlu; Meriç Şengöz
Journal:  Radiat Oncol J       Date:  2022-03-28

Review 8.  STAT3 Contributes to Radioresistance in Cancer.

Authors:  Xuehai Wang; Xin Zhang; Chen Qiu; Ning Yang
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

9.  Multiple Irradiation Affects Cellular and Extracellular Components of the Mouse Brain Tissue and Adhesion and Proliferation of Glioblastoma Cells in Experimental System In Vivo.

Authors:  Maxim O Politko; Alexandra Y Tsidulko; Oxana A Pashkovskaya; Konstantin E Kuper; Anastasia V Suhovskih; Galina M Kazanskaya; Lyubov S Klyushova; Dmitry K Sokolov; Alexander M Volkov; Evgenii E Kliver; Alexander A Zheravin; Svetlana V Aidagulova; Elvira V Grigorieva
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

10.  Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.

Authors:  Joel R Garbow; Tanner M Johanns; Xia Ge; John A Engelbach; Liya Yuan; Sonika Dahiya; Christina I Tsien; Feng Gao; Keith M Rich; Joseph J H Ackerman
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.